MorphoSys AG
NASDAQ:MOR

Watchlist Manager
MorphoSys AG Logo
MorphoSys AG
NASDAQ:MOR
Watchlist
Price: 18.96 USD 2.43% Market Closed
Market Cap: 2.9B USD

MorphoSys AG
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

MorphoSys AG
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
MorphoSys AG
XETRA:MOR
Revenue
€203.5m
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
10%
BioNTech SE
NASDAQ:BNTX
Revenue
€2.8B
CAGR 3-Years
-47%
CAGR 5-Years
91%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Revenue
€535.2m
CAGR 3-Years
73%
CAGR 5-Years
98%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Revenue
€84.8m
CAGR 3-Years
-17%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Revenue
€635.2m
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
1%
Formycon AG
XETRA:FYB
Revenue
€69.7m
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
19%
No Stocks Found

MorphoSys AG
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments. This platform not only serves their internal pipeline but also provides a significant source of revenue through collaborations and licensing agreements with major pharmaceutical giants, enabling MorphoSys to strike timely alliances that bolster both innovation and profitability. Central to MorphoSys's business model is its dual focus: advancing its own pipeline of antibody-based therapeutics while simultaneously offering its technological platforms to partners. This symbiosis allows the company to generate revenue through milestone payments and royalties as partnered drugs advance through clinical trials and into the market. A key asset in its lineup is Monjuvi, a groundbreaking treatment for lymphoma, which underscores the firm's capability to evolve from tech-driven operations to delivering market-ready solutions. As markets grow increasingly competitive, MorphoSys's strategic prowess lies in balancing its R&D investments with collaborative ventures, ensuring a steady revenue stream and a robust presence in the biopharmaceutical realm.

MOR Intrinsic Value
Not Available

See Also

What is MorphoSys AG's Revenue?
Revenue
203.5m EUR

Based on the financial report for Mar 31, 2024, MorphoSys AG's Revenue amounts to 203.5m EUR.

What is MorphoSys AG's Revenue growth rate?
Revenue CAGR 10Y
10%

Over the last year, the Revenue growth was -32%. The average annual Revenue growth rates for MorphoSys AG have been 18% over the past three years , 18% over the past five years , and 10% over the past ten years .

Back to Top